← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Tumor necrosis factor alpha (TNF-alpha) inhibitors
opinercept
L04AB07
Forms & Strengths
- Injection: 5mg/mL
- Lyophilized powder for injection: 5mg/vial
Adult Dosing
- Initial dose: 10mg IV on days 1 and 15 of a 28-day cycle
- Subsequent doses: 15mg IV on day 1 of each 28-day cycle
- Dose reduction for adverse reactions: 10mg IV on day 1 of each 28-day cycle
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of adults with moderate to severe active rheumatoid arthritis
- Treatment of adults with active psoriatic arthritis
- Treatment of adults with active ankylosing spondylitis
Mechanism of Action
- Selective inhibitor of tumor necrosis factor-alpha (TNF-alpha) that acts as a decoy receptor
- Prevents TNF-alpha interaction with cell surface TNF receptors
- Reduces inflammation and slows disease progression
Contraindications
- Hypersensitivity to opinercept or any component of the formulation
- Congestive heart failure grades III and IV
- Active or untreated latent tuberculosis
Adverse Reactions
- Upper respiratory tract infection
- Headache
- Hypertension
- Abdominal pain
- Injection-site reactions
- Increased risk of serious infections
- Potential for increased risk of malignancies
Drug Interactions
- Concomitant use with anakinra, abatacept, or other biologic DMARDs may increase the risk of serious infections
- Concomitant use with live or attenuated vaccines may increase the risk of infections
- Concomitant use with immunosuppressants may increase the risk of serious infections
Curated Content: Needs Vetting Before Put to Clinical Use